Clinical use of factor VIII and factor IX concentrates

Blood Transfusion

Volumn 11, Issue SUPPL. 4, 2013, Pages

  Morfini, Massimo ^a   Coppola, Antonio ^b   Franchini, Massimo ^c   Minno, Giovanni Di ^b  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b FEDERICO II UNIVERSITY HOSPITAL   (Italy)

^c CARLO POMA HOSPITAL   (Italy)

Author keywords

Factor IX concentrate; Factor VIII concentrate; Haemophilia; Safety; Treatment

Indexed keywords

BLOOD CLOTTING FACTOR 8 CONCENTRATE; BLOOD CLOTTING FACTOR 8 PLUS VON WILLEBRAND FACTOR; BLOOD CLOTTING FACTOR 9 CONCENTRATE; EMOCLOT D I; FANHDI; FIXNOVE; HAEMOBIONINE; HAEMOCTIN; RECOMBINANT BLOOD CLOTTING FACTOR 8; RECOMBINANT BLOOD CLOTTING FACTOR 9; REFACTOR AF; TALATE; UNCLASSIFIED DRUG;

BLEEDING; CREUTZFELDT JAKOB DISEASE; DISEASE SEVERITY; DRUG INDICATION; DRUG SAFETY; HEMOPHILIA; HEMOPHILIA A; HEMOPHILIA B; HUMAN; ITALY; RECOMMENDED DRUG DOSE; REVIEW; VIRUS INFECTION; VON WILLEBRAND DISEASE;

COAGULANTS; FACTOR IX; FACTOR VIII; HUMANS;

EID: 84885613207     PISSN: 17232007     EISSN: None     Source Type: Journal    
DOI: 10.2450/2013.010s     Document Type: Review

References (73)

1. Thompson AR. Structure and function of the factor VIII gene and protein. Semin Thromb Hemost 2003; 29: 11-22. (Pubitemid 36250259)
2. Mannucci PM, Tuddenham EGD. The hemophilias - from royal genes to gene therapy. N Engl J Med 2001; 344: 1773-9. (Pubitemid 32497033)
3. Stonebraker JS, Bolton-Maggs PH, Soucie JM, et al. A study of variations in the reported haemophilia A prevalence around the world. Haemophilia 2010; 16: 20-32.
4. White GC 2nd, Rosendaal F, Aledort LM, et al. Definition in hemophilia. Recommendation of scientific subcommittee on factor VIII and factor IX of scientific and standardization committee of the International Society of Thrmbosis and Haemostasis. Thromb Haemost 2001; 85: 560. (Pubitemid 32233035)
5. van Dijk K, Fischer K, van der Bom JG, et al. Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed. Haemophilia 2005; 11: 438-43. (Pubitemid 41283110)
6. Pavlova A, Oldenburg J. Defining severity of haemophilia: More than factor levels. Semin Thromb Hemost 2013; DOI 10.1055/s-0033-1354426.
7. Tagliaferri A, Di Perna C, Riccardi F, et al. The natural history of mild haemophilia: a 30-year single centre experience. Haemophilia 2012; 18: 166-74.
8. Aronstam A, Rainsford SG, Painter MJ. Patterns of bleeding in adolescent with severe haemophilia A. Br Med J 1975; 1: 469-70. (Pubitemid 9114998)
9. Peyvandi F, Lak M, Mannucci PM. Factor XI manifestations in Iranians: its clinical symptoms in comparison with those of classic hemophilia. Haematologica 2002; 87: 512-4. (Pubitemid 34533277)
10. Aledort L, Haschmeyer RH, Pettersson H. A longitudinal study of orthopaedic outcomes for severe factor-VIII-deficient haemophiliacs. The Orthopaedic Outcome Study Group. J Intern Med 1994; 236: 391-9. (Pubitemid 24323199)
11. Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013; 19: e1-47.
12. Santagostino E, Fasulo MR. Hemophilia A and hemophilia B: different types of diseases? Semin Thromb Hemost 2013; DOI 10.1055/s-0033-1353996.
13. Mannucci PM, Franchini M, Castaman G, Federici AB; Italian Association of Hemophilia Centers. Evidence-based recommendations on the treatment of von Willebrand disease in Italy. Blood Transfus 2009; 7: 117-26.
14. Franchini M, Mannucci PM. Past, present and future of hemophilia: a narrative review. Orphanet J Rare Dis 2012; 7: 24.
15. Mannucci PM. Back to the future: a recent history of haemophilia treatment. Haemophilia 2008; 14 (Suppl 3): 10-8. (Pubitemid 351722377)
16. Ofosu FA, Freedman J, Semple JW. Plasma-derived biological medicines used to promote haemostasis. Thromb Haemost 2008; 99: 851-62. (Pubitemid 351705301)
17. Nilsson IM, Berntorp E, Löfqvist T, Pettersson H. Twentyfive years experience of prophylactic treatment in severe haemophilia A and B. J Intern Med. 1992; 232: 25-32.
18. Fischer K, van der Bom JG, Mauser-Bunschoten EP, et al. The effects of postponing prophylactic treatment on longterm outcome in patients with severe hemophilia. Blood. 2002; 99: 2337-41. (Pubitemid 34525418)
19. Tabor E. The epidemiology of virus transmission by plasma derivatives: clinical studies verifying the lack of transmission of hepatitis B and C viruses and HIV type 1. Transfusion 1999; 39: 1160-8.
20. White GC, McMillan CW, Kingdon HS, Shoemaker CB. Use of recombinant antihemophilic factor in the treatment of two patients with classic hemophilia. N Engl J Med 1989; 320: 166-70. (Pubitemid 19033095)
21. Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007; 357: 535-44. (Pubitemid 47236278)
22. Coppola A, Franchini M, Tagliaferri A. Prophylaxis in people with hemophilia. Thromb Haemost 2009; 101: 674-81.
23. Franchini M, Mannucci PM. Co-morbidities and quality of life in elderly persons with haemophilia. Br J Haematol 2010; 148: 522-33.
24. Tagliaferri A, Rivolta GF, Iorio A, et al; for the Italian Association of Hemophilia Centers. Mortality and causes of death in Italian persons with haemophilia, 1990-2007. Haemophilia 2010; 16: 437-46.
25. Coppola A, Tagliaferri A, Franchini M. The management of cardiovascular diseases in patients with hemophilia. Semin Thromb Hemost 2010; 36: 91-102.
26. Franchini M. Haemophilia and cancer: a personal perspective. Blood Transfus 2013; 11: 26-31.
27. Coppola A, Santoro C, Franchini M, et al. Emerging issues on comprehensive hemophilia care: preventing, identifying and monitoring age-related comorbidities. Semin Thromb Hemost 2013; DOI 10.1055/s-0033-1354421.
28. Franchini M, Mannucci PM. Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice. Br J Clin Pharmacol 2011; 72: 553-62.
29. Franchini M, Lippi G. Recombinant FVIII concentrates. Semin Thromb Hemost 2010; 36: 493-7.
30. Franchini M, Frattini F, Crestani S, et al. Treatment of hemophilia B: focus on recombinant factor IX. Biologics 2013; 7: 33-8.
31. Mannucci PM, Kempton C, Millar C, et al. Pharmacokinetics and safety of a novel recombinant human von Willebrand factor manufactured with a plasma-free method: a prospective clinical trial. Blood 2013; 122: 648-57.
32. Brooker M. Registry of clotting factor concentrates. Ninth Edition. Facts and Figures Monographs, n. 6. World Federation of Hemophilia, Montreal, QC, Canada, 2012. http://www.wfh.-org. Accessed on 13/08/2013.
33. Rosendaal G, Lafeber FP. Pathogenesis of hemophilic arthropathy. Haemophilia 2006; 12 (Suppl 3): 117-21.
34. Ahlberg A. Haemophilia in Sweden. VII. Incidence, treatment and prophylaxis of arthropathy and other musculo-skeletal manifestations of hemophilia A and B. Acta Orthop Scand Suppl 1965; Suppl 77: 3-132.
35. Gringeri A, Lundin B, Mackensen SV, et al. A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study). J Thromb Haemost 2011; 9: 700-10.
36. Tagliaferri A, Franchini M, Coppola A, et al. Effects of secondary prophylaxis started in young-adult hemophiliacs. Haemophilia 2008; 14: 945-51.
37. Gringeri A, Lambert T, Street A, Aledort L; Adolescent/Adult Prophylaxis Expert Working Group of the International Prophylaxis Study Group. Tertiary prophylaxis in adults: is there a rationale? Haemophilia. 2012; 18: 722-8.
38. Ljung R. Prevention of bleeding in haemophilia: trends, overcoming barriers and future treatment options. Haemophilia 2007; 13 (Suppl 2): 1-3. (Pubitemid 47034487)
39. Coppola A, Tagliaferri A, Di Capua M, Franchini M. Prophylaxis in children with hemophilia: evidence-based achievements, old and new challenges. Semin Thromb Hemost 2012; 38: 79-94.
40. Feldman BN, Pai M, Rivard GE et al. Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study. J Thromb Haemost 2006; 4: 1228-36.
41. Collins PW, Björkman S, Fischer K, et al. Factor VIII requirement to maintain a target plasma level in the prophylactic treatment of severe hemophilia A: influences of variance in pharmacokinetics and treatment regimens. J Thromb Haemost 2010; 8: 269-75.
42. Santoro C, Baldacci E, Mercanti C, Mazzucconi MG. Tailored vs. standard dose prophylaxis in children with haemophilia A. Semin Thromb Hemost 2013; DOI 10.1055/s-0033-1354419.
43. Biss TT, Chan AK, Blanchette VS, et al. The use of prophylaxis in 2663 children and adults with haemophilia: results of the 2006 Canadian national haemophilia prophylaxis survey. Haemophilia 2008; 14: 923-30.
44. Franchini M, Coppola A, Molinari AC, et al. Forum on: the role of recombinant factor VIII in children with severe haemophilia A. Haemophilia. 2009; 15: 578-86.
45. Abbonizio F, Gianpaolo A, Arcieri R, Hassan HJ e Associazione Italiana Centri Emofilia. Registro Nazionale Coagulopatie Congenite. Rapporto 2011. Rapporti ISTISAN 12/55.
46. Tagliaferri A, Rivolta GF, Coppola A, et al. Prophylaxis versus on-demand therapy through economic report (POTTER) study: Preliminary data from the final five-year analysis. Haemophilia 2012; 18 (Suppl 3): 160 (abstract).
47. Hermans C, De Moerloose P, Fischer K, et al. Management of acute haemarthrosis in haemophilia A without inhibitors: literature review, European survey and recommendations. Haemophilia 2011; 17: 383-92.
48. Santagostino E, Mannucci PM. Guidelines on replacement therapy for haemophilia and inherited coagulation disorders in Italy. Haemophilia 2000; 6: 1-10. (Pubitemid 30113894)
49. Hermans C, Altisent C, Batorova A, et al. Replacement therapy for invasive procedures in patients with haemophilia: literature review, European survey and recommendations. Haemophilia 2009; 15: 639-58.
50. Martinowitz U, Schulman S. Coagulation factors concentrations by continuous infusion Transfusion Medicine Reviews 1997; 11: 56-63. (Pubitemid 27083616)
51. DiMichele D, Hoots WK, Pipe SW, et al. International workshop on immune tolerance induction: consensus recommendations. Haemophilia 2007; 13 (Suppl 1): 1-22. (Pubitemid 47009242)
52. Coppola A, Di Minno MN, Santagostino E. Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence-based approaches. Br J Haematol 2010; 150: 515-528.
53. Hay CR, DiMichele DM; International Immune Tolerance Study. The principal results of the International Immune Tolerance Study: a randomized dose comparison. Blood 2012; 119: 1335-44.
54. Colowick AB, Bohn RL, Avorn J, Ewenstein BM. Immune tolerance induction in hemophilia patients with inhibitors: costly can be cheaper. Blood 2000; 96: 1698-702. (Pubitemid 30661051)
55. Coppola A, Margaglione M, Santagostino E et al. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of hemophilia A patients with highresponding inhibitors. J Thromb Haemost 2009; 7: 1809-15.
56. Coppola A, Franchini M, Makris M, et al. Thrombotic adverse events to coagulation factor concentrates for treatment of patients with haemophilia and von Willebrand disease: a systematic review of prospective studies. Haemophilia 2012; 18: e173-87.
57. Goudemand J, Scharrer I, Berntorp E, et al. Pharmacokinetic studies on Wilfactin, a von Willebrand factor concentrate with a low factor VIII content treated with three virus-inactivation/removal methods. J Thromb Haemost 2005; 3: 2219-27. (Pubitemid 41727200)
58. Wight J, Paisley S. The epidemiology of inhibitors in haemophilia A. A systematic review. Haemophilia 2003; 9: 418-35. (Pubitemid 36874391)
59. Dasgupta S, Repessé Y, Bayry J, et al. VWF protects FVIII from endocytosis by dendritic cells and subsequent presentation to immune effectors. Blood 2007; 109: 610-2. (Pubitemid 46105959)
60. Mancuso ME, Mannucci PM, Rocino A, et al. Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A. J Thromb Haemost 2012; 10: 781-90.
61. Mannucci PM, Gringeri A, Peyvandi F, Santagostino E. Factor VIII products and inhibitor development: the SIPPET study (survey of inhibitors in plasma-product exposed toddlers). Haemophilia 2007; 13 (Suppl 5): 65-8. (Pubitemid 350253407)
62. Gouw SC, van der Bom JG, Auerswald G, et al. for the CANAL Study group. Recombinant versus plasma-derived factor VIII products and the development of inhibitors in previously untreated patients with severe hemophilia A: the CANAL cohort study. Blood 2007; 109: 4693-7. (Pubitemid 46827760)
63. Gouw SC, van der Bom JG, Ljiung R, et al. for the PedNet and RODIN Study Group. Factor VIII products and inhibitor development in severe hemophilia A. N Engl J Med 2013; 368: 231-9.
64. Makris M, Fischer K, Gilman EA; European Haemophilia Safety Surveillance System (EUHASS). Annual Report 3. June 13, 2012.
65. Franchini M, Coppola C, Rocino A; on behalf the Italian Association of Hemophilia Centers (AICE) Working Group. Systematic review of the role of FVIII concentrates in inhibitor development in previously untreated patients with severe hemophilia A: a 2013 update. Semin Thromb Hemost 2013; DOI 10.1055/s-0033-1356715
66. Azzi A, Ciappi S, Zakvrewska K, et al. Human parvovirus B 19 infection in hemophiliacs first infused with two high-purity, virally attenuated, factor VIII concentrates. Am J Hematol 1992; 39: 228-30.
67. Soucie JM, Monahan PE, Kulkarni R, et al. Evidence for the continued transmission of parvovirus B19 in patients with bleeding disorders treated with plasma-derived factor concentrates. Transfusion 2013; 53: 1143-4.
68. Norja P, Lassila R, Makris M. Parvovirus transmission by blood products - a cause for concern? Br J Haematol 2012; 159: 385-93.
69. Peden A, McCardle L, Head MW et al. Variat CJD infection in the spleen of a neurologically asymptomatic UK adult patient with haemophilia. Haemophilia 2010: 16: 296-304.
70. Keeling D, Tait C, Makris M. Guideline on the selection and use of therapeutic products to treat haemophilia and other hereditary bleeding disorders. A United Kingdom Haemophilia Centre Doctors' Organisation (UKHCDO) guideline approved by the British Committee for Standards in Haematology. Haemophilia 2008; 14: 671-84.
71. Batlle J, Villar A, Liras A, et al. Consensus opinion for the selection and use of therapeutic products for the treatment of haemophilia in Spain. Blood Coagul Fibrinolysis. 2008; 19: 333-40.
72. Medical and Scientific Advisory Council. MASAC Document no. 169. MASAC Recommendation Regarding the Use of Recombinant Clotting Factor Products with Respect to Pathogen Transmission. 2006: http://www.hemophilia.org/NHFWeb/ Resource/StaticPages/menu0/menu5/menu57/169. pdf. Accessed on 13/08/2013.
73. Franchini M, Coppola A, Rocino A, et al; on behalf the Italian Association of Hemophilia Centers (AICE) Study Group. Perceived challenges and attitudes to regimen and product selection from Italian haemophilia treaters. The 2013 AICE survey. Haemophilia 2013; submitted.